Perfil de la empresa · Healthcare

Royalty Pharma Plc

RPRX · EE. UU.
Industria
生物制药特许权
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
25 de marzo de 1993
Empleados
100
Sitio web
www.royaltypharma.com
Precio actual
$56.66
En vivo · 5 de octubre de 2026
Compra razonable
≤ $40
Entrada con margen de seguridad
Puntuación de crecimiento Baillie
50/100
Media
Buffett Score
58/100
Media
Valor intrínseco · Rango en tres niveles Precio actual $56.66 En vivo · Dentro del rango de valor intrínseco razonable

Rango de valoración compuesto · conservador $36–$40 / razonable $52–$66 / optimista $84–$90. A $56.66, Dentro del rango de valor intrínseco razonable.

Al publicar $58.41 (20 de septiembre de 2026)

Resumen financiero
Capitalización33,03 mil M US$
Ingresos (TTM)2536 M US$
EBITDA1557,37 M US$
Margen neto32,02 %
ROE13,97 %
PER (TTM)30,9
PER previsto29,41
PEG1,34
BPA1,85 US$
Rentabilidad por dividendo1,58 %
Rango de 52 semanas34,56 US$ – 64,38 US$
Precio objetivo de analistas65,13 US$
Recomendación de analistas4.5 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Sobre la empresa

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Información general

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.

Análisis sobre este valor
50/100 Mantener Royalty Pharma: $3.254bn of Portfolio Receipts and 48% Deal Share Meet a 24% Expiry Wall by 2030 and a $58.41 Price That Already Pays for the Platform Royalty Pharma is a specialty-finance platform whose loan book is denominated in molecules: it buys contractual percentages of other companies' drug sales, funds late-stage development in exchange for synthetic royalties, and collects near the top of the income statement while somebody else carries the commercial cost. 2025 Portfolio Receipts were $3.254bn against only $288m of cash operating and professional costs, and the company sourced 48% of announced biopharma-royalty transaction value over 2020-2025, but roughly 24% of 2025 Royalty Receipts sits on products whose royalty duration substantially ends by 2030, and hitting the $4.7bn 2030 target needs $2.0-2.5bn of deployment every year. Rating Hold: at $58.41 the shares are near 11.6 times estimated 2026 Portfolio Cash Flow but 19-23 times owner earnings once $1.1-1.4bn of replacement deployment is charged as economic maintenance, above the $46-50 conservative value, so the report waits for $36-40 before committing new capital. Royalty Pharma plcRPRX · EE. UU.生物制药特许权20 de septiembre de 2026